2. NF-κB
  3. NF-κB
  4. Propacetamol hydrochloride

Propacetamol hydrochloride is an orally active prodrug of paracetamol and an inducer of acute liver injury models, with multiple properties including antinociception, antioxidation and gastroprotection. Propacetamol hydrochloride potentiates Tramadol and attenuates Aspirin (HY-14654)-induced gastric mucosal damage and lipid peroxidation. Under specific conditions, Propacetamol hydrochloride also acts as a hepatotoxic inducer, triggering acute liver injury, oxidative stress and apoptosis, with strain differences in toxicity sensitivity. Propacetamol hydrochloride can be used in the research of acute liver injury, drug-induced hepatotoxicity and gastric mucosal damage.

For research use only. We do not sell to patients.

Propacetamol hydrochloride

Propacetamol hydrochloride Chemical Structure

CAS No. : 66532-86-3

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
100 mg In-stock
250 mg In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Propacetamol hydrochloride:

Propacetamol hydrochloride Related Antibodies

Top Publications Citing Use of Products

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Propacetamol hydrochloride is an orally active prodrug of paracetamol and an inducer of acute liver injury models, with multiple properties including antinociception, antioxidation and gastroprotection. Propacetamol hydrochloride potentiates Tramadol and attenuates Aspirin (HY-14654)-induced gastric mucosal damage and lipid peroxidation. Under specific conditions, Propacetamol hydrochloride also acts as a hepatotoxic inducer, triggering acute liver injury, oxidative stress and apoptosis, with strain differences in toxicity sensitivity. Propacetamol hydrochloride can be used in the research of acute liver injury, drug-induced hepatotoxicity and gastric mucosal damage[1][2][3][4][5].

In Vitro

Propacetamol induces acute liver injury through the following mechanisms: it is metabolized by CYP2E1 to form the toxic intermediate N-acetyl-p-benzoquinone imine (NAPQI), which depletes hepatic GSH and triggers oxidative stress, inflammatory responses and apoptosis; it also inhibits UGT1A1 expression and activates the JNK/ERK pathway. Its core activity mimics the toxicological effects of acetaminophen overdose[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Propacetamol hydrochloride Related Antibodies
In Vivo

Propacetamol hydrochloride (600-1200 mg/kg; i.p.; single injection) induces severe acute liver injury in male BALB/cByJNarl mice at 600 mg/kg, while 1200 mg/kg is lethal, causing 100% mortality within 14 h[2].
Propacetamol (1200-1400 mg/kg; i.p.; single dose) induces acute lethal liver injury in BALB/c mice, with 1400 mg/kg causing 100% mortality by 168 h and 1200 mg/kg reducing survival to 10% over the same period[3].
Propacetamol (1200-1800 mg/kg; i.p.; single dose) induces acute liver injury in C57BL/6 mice with strain-specific tolerance, with 1600 and 1800 mg/kg causing 100% mortality by 168 h and 1200 mg/kg reducing survival to 50% over the same period[3].
Propacetamol (200 mg/kg; i.p.; single dose) produces significant antinociception in mice with acetic acid-induced persistent visceral pain, as measured by reduced abdominal writhing responses[4].
Propacetamol (270-540 mg/kg; i.p.; single dose) does not produce significant antinociception in female mice tested with the hot plate acute thermal pain assay[4].
Propacetamol (125-500 mg/kg; i.g.; single dose; 30 min before ASA) exerts a dose-dependent gastroprotective effect against ASA-induced gastric ulceration in male Wistar rats, with the 500 mg/kg dose reducing ulcer area by 52.9% and gastric mucosal MDA levels by 66.9%, and supporting adaptive antioxidant responses via maintenance of elevated gastric UA and glutathione levels[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/cByJNarl (six-week-old male, 20-22 g, acute liver injury induced by propacetamol injection)[2]
Dosage: 600 mg/kg (acute liver injury induction); 1200 mg/kg (lethal model)
Administration: i.p.; single injection
Result: Induced significant acute liver injury, characterized by dark red discoloration of liver tissue, marked elevations in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, severe histopathological liver damage (cell vacuolization, membrane loss, nuclear disappearance, bleeding, and elevated histopathological scores), reduced hepatic glutathione (GSH) levels, increased thiobarbituric acid reactive substances (TBARS) and 3-nitrotyrosine (3-NT) levels, suppressed superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activities, increased serum tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) levels, increased hepatic Bax expression and Bax/Bcl-2 ratio at 6 h post-injection, increased cleaved caspase-3 expression at 12 h post-injection, 83.00 ± 2.89% TUNEL-positive liver area at 18 h post-injection, increased hepatic cytochrome P450 2E1 (CYP2E1) expression, reduced UDP-glucuronosyltransferase family 1 member A1 (UGT1A1) expression, increased nuclear nuclear factor erythroid 2-related factor 2 (Nrf2) levels at 6 h post-injection, reduced Nrf2 and glutamate cysteine ligase catalytic subunit (GCLC) levels at 18 h post-injection, increased heme oxygenase 1 (HO-1) levels at 18 h post-injection, increased phosphorylated c-jun-N-terminal kinase (p-JNK)/JNK and phosphorylated extracellular signal-regulated kinase (p-ERK)/ERK ratios at 6 h post-injection, and increased hepatic receptor-interacting serine/threonine-protein kinase 1 (RIP1) expression at 6 h post-injection.\nCaused 100% mortality of all tested mice within 14 h post-injection without post-treatment.
Animal Model: BALB/cByJNarl (male, 5 weeks old, 20-22 g, acute liver injury induced by intraperitoneal propacetamol injection)[3]
Dosage: 1200 mg/kg; 1400 mg/kg
Administration: i.p.; single dose
Result: Resulted in 10% survival at 168 h post-injection (1200 mg/kg).\nResulted in 0% survival at 168 h post-injection (1400 mg/kg).
Animal Model: C57BL/6JNarl (male, 5 weeks old, 20-22 g, acute liver injury induced by intraperitoneal propacetamol injection)[3]
Dosage: 1200 mg/kg; 1400 mg/kg; 1600 mg/kg; 1800 mg/kg
Administration: i.p.; single dose
Result: Resulted in 50% survival at 168 h post-injection (1200 mg/kg).\nResulted in 40% survival at 168 h post-injection (1400 mg/kg).\nResulted in 0% survival at 168 h post-injection (1600 mg/kg).\nResulted in 0% survival at 168 h post-injection (1800 mg/kg).
Animal Model: Wistar (male, 240-270 g, ASA-induced gastric ulceration)[5]
Dosage: 125 mg/kg; 250 mg/kg; 500 mg/kg
Administration: i.g.; single dose; 30 min before ASA
Result: Reduced ASA-induced gastric ulcer area by 22.0% (125 mg/kg), 38.5% (250 mg/kg), and 52.9% (500 mg/kg).\nReduced ASA-elevated gastric mucosal MDA levels by 48.4% (125 mg/kg), 56.3% (250 mg/kg), and 66.9% (500 mg/kg).\nElevated gastric mucosal UA levels above control values and significantly higher than the ASA-only group at 250 mg/kg and 500 mg/kg.\nDecreased gastric mucosal GSH and GSSG levels compared to the ASA-only group but remained significantly higher than control values.\nCaused gastric mucosa to appear almost normal, with only occasional bending of superficial epithelium and focal desquamation observed.\nReduced plasma MDA levels by a slight, non-significant 1.5% at 500 mg/kg compared to the ASA-only group.\nElevated plasma UA levels above control values, increasing by 19.8% (250 mg/kg) and 26.7% (500 mg/kg) compared to the ASA-only group.
Molecular Weight

300.79

Formula

C14H21ClN2O3
CAS No.
Appearance

Solid

Color

White to light yellow

SMILES

O=C(OC1=CC=C(NC(C)=O)C=C1)CN(CC)CC.[H]Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, stored under nitrogen, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

Solvent & Solubility
In Vitro: 

H2O : 200 mg/mL (664.92 mM; Need ultrasonic)

DMSO : 25 mg/mL (83.11 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.3246 mL 16.6229 mL 33.2458 mL
5 mM 0.6649 mL 3.3246 mL 6.6492 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.74%

SDS (394 KB)

COA (242 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / H2O 1 mM 3.3246 mL 16.6229 mL 33.2458 mL 83.1145 mL
5 mM 0.6649 mL 3.3246 mL 6.6492 mL 16.6229 mL
10 mM 0.3325 mL 1.6623 mL 3.3246 mL 8.3114 mL
15 mM 0.2216 mL 1.1082 mL 2.2164 mL 5.5410 mL
20 mM 0.1662 mL 0.8311 mL 1.6623 mL 4.1557 mL
25 mM 0.1330 mL 0.6649 mL 1.3298 mL 3.3246 mL
30 mM 0.1108 mL 0.5541 mL 1.1082 mL 2.7705 mL
40 mM 0.0831 mL 0.4156 mL 0.8311 mL 2.0779 mL
50 mM 0.0665 mL 0.3325 mL 0.6649 mL 1.6623 mL
60 mM 0.0554 mL 0.2770 mL 0.5541 mL 1.3852 mL
80 mM 0.0416 mL 0.2078 mL 0.4156 mL 1.0389 mL
H2O 100 mM 0.0332 mL 0.1662 mL 0.3325 mL 0.8311 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Propacetamol hydrochloride Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Propacetamol66532-86-3NF-κBNuclear factor-κBNuclear factor-kappaBgastroprotective agentratsapoptosisantinociceptive agentacute liver injurygastric mucosal lesionsoxidative stresshepatotoxicityinflammatory cytokine productionmiceInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Propacetamol hydrochloride
Cat. No.:
HY-108292
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (394 KB) Français - FR (394 KB) Deutsch - DE (394 KB) Norwegian - NO (394 KB) Español - ES (394 KB) Swedish - SV (394 KB) Italian - IT (394 KB) Korean - KR (394 KB) Portuguese - PT (394 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.